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What can be learned using 
microarrays?
MD Stegall1 and W Park1
Whole-genome microarrays identify large numbers of gene expression 
changes that appear specifically related to disease states such as 
antineutrophil cytoplasmic autoantibody (ANCA) and systemic lupus 
erythematosus. Although understanding this enormous volume of 
esoteric data is difficult, a few basic concepts regarding microarray 
studies can significantly improve the general reader’s comprehension.
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High-throughput microarrays offer the 
promise of new insights into common dis-
eases. However, both the amount and the 
type of data generated can make data pres-
entation diﬃcult and leave a reader asking, 
‘Can I learn anything from this article?’ We 
present here some of our thoughts regard-
ing what a more general reader might 
consider in approaching a study that uses 
microarrays, including speciﬁc comments 
on the article by Alcorta et al.1 (this issue).
Alcorta et al.1 examined gene expression 
in peripheral blood leukocytes of antineu-
trophil cytoplasmic autoantibody (ANCA) 
and systemic lupus erythematosus (SLE) 
patients. Leukocytes from healthy donors 
were used as controls serving as the base-
line for gene expression comparisons. Let 
us assess how this fairly typical study uses 
microarrays.
Most clinical microarray projects have 
one of two goals: (1) to generate a list of 
‘signature’ genes that are able to classify 
patients into one group or another; or (2) to 
generate a list of genes that provides insight 
into the underlying biological processes 
involved in speciﬁc disease states. If the 
goal is to generate a list of signature genes, 
this usually is best accomplished with the 
use of a large and potentially heterogeneous 
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group of patients. It is unlikely that sig-
natures generated from small numbers 
of patients will be applicable to a broad 
population. Signature-gene data are typi-
cally displayed as a ‘heat map’. In their 
current study, Alcorta et al.1 have used 
this approach to display gene expression 
signatures in peripheral blood leukocytes 
to diﬀerentiate SLE from ANCA. With just 
a few hundred genes as signatures, they 
found that 69.4% (50 of 72) of patients 
with SLE demonstrated the SLE signature 
and 77% (20 of 26) of patients with ANCA 
demonstrated the ANCA signature. Only 
nine SLE patients demonstrated the ANCA 
cluster. Another signature contained 25 of 
28 healthy donors. Although these signa-
tures do not perfectly classify the patients 
into each group, these results are typical 
of the gene-classiﬁer approach. An alter-
native, increasingly common approach 
is to ﬁrst create the signature genes from 
a smaller test sample and then run these 
against an independent validation sample 
set that conﬁrms or refutes the ability of the 
signature to accurately predict each patient 
group. The ability of signature-gene lists to 
accurately classify patients probably var-
ies with the disease process, but it is worth 
noting that in one well-studied area (breast 
cancer), multiple classiﬁers have not per-
formed well in cross-validation studies.2,3
If the goal of the microarray study is to 
provide insight into the underlying patho-
genesis of disease, a more homogeneous 
group of patients is usually preferred, 
with similar demographic characteristics, 
therapies, disease progression, outcome, 
and so on. In this setting, it is more likely 
that altered gene expression associated with 
speciﬁc biological processes or metabolic 
pathways is due to the disease process and 
not due to patient heterogeneity. The study 
of Alcorta et al.1 is limited in this respect. 
For example, the majority of patients were 
on immunomodulatory agents, using 
combinations too heterogeneous to assess. 
Because the gene expression studies were 
performed on peripheral blood leukocytes, 
these immunomodulatory agents could 
have an important impact on gene expres-
sion and mask important changes associ-
ated with each group. Patients also were at 
various stages of disease.
Even when a ﬁnal list of genes has been 
decided on for more detailed study and 
validation using quantitative real-time 
polymerase chain reaction, most of us get 
confused, as the most popular microarrays 
contain thousands of genes for esoteric 
proteins. For example, Alcorta et al.1 found 
that the genes with the greatest correlation 
with ANCA included ring-ﬁnger protein 
24, ubiquitin-conjugating enzyme E2, v-
ets, and lymphocyte α-kinase. Given the 
relatively obscure nature of these genes, the 
natural tendency is to jump down to famil-
iar genes (perforin 1 and the interleukin-1 
receptor rekindled our interest), but doing 
so biases the interpretation of the data and 
prevents the discovery of new genes that 
may be involved in a given biological proc-
ess. It is for this reason that an increasingly 
acceptable alternative is to present these 
data in terms of which speciﬁc biological 
pathways appear to be altered. The authors 
did this using the Gene Ontology catego-
ries (Aﬀymetrix Gene Ontology, Aﬀyme-
trix). This program identifies common 
members of functional gene families (for 
example, immunity, stress, and wounding 
were found in the study by Alcorta et al.1). 
However, we ﬁnd these categories too gen-
eral to provide meaningful interpretation 
of the data. In our opinion, a more useful 
computer program identiﬁes gene expres-
sion within speciﬁc biological pathways. 
These so-called ‘canonical’ pathway pro-
grams — for example, Ingenuity Analy-
sis (Ingenuity Systems) and MetaCore 
(GeneGo) — illustrate changes in gene 
expression in pathways in a more detailed 
fashion. A recent example from our 
own work in kidney transplant biopsies, 
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presented here (Figure 1), shows gene 
expression alterations in the interferon and 
integrin signaling pathways.4 The beneﬁt 
of using this approach is that, if multiple 
members of the same biological pathway 
are associated with a speciﬁc process, then 
potentially that pathway is truly involved in 
the process. Perhaps most importantly, this 
approach allows researchers to move away 
from selecting a handful of individual mol-
ecules to explore further without knowing 
how or whether they are interrelated with 
other signiﬁcantly altered genes.
Two methodological considerations also 
should be remembered by any reader. First, 
the statistical analyses for these studies can 
vary. Because microarrays contain so many 
genes, some groups will use a combina-
tion of statistical approaches to identify 
the genes considered in further analyses. 
Alcorta et al.1 not only chose to use a P 
value of less than 0.01 to determine sta-
tistical signiﬁcance, but also required that 
the genes have a fold change of at least 1.8. 
Dual requirements such as these, aimed 
at ﬁnding ‘really signiﬁcant’ changes, are 
common in microarray studies, given that 
hundreds of genes might be altered solely 
by chance. However, there is no statistical 
reason for this approach, and it is likely 
to omit important genes that actually are 
altered.5 A second methodological consid-
eration is that microarray platforms and the 
speciﬁc chip type used also vary and can 
have a signiﬁcant impact on the data gener-
ated. Although most platforms and chips 
are adequate for any study, we and others 
have identiﬁed signiﬁcant issues related to 
improper probe sequence design, incorrect 
assignment of a gene name to a probe set 
(termed annotation), and poor detection of 
low levels of gene expression.6 These issues 
must be considered for proper data inter-
pretation with either the gene-classiﬁer or 
the biological-process approach.
Finally, microarray studies result in large 
amounts of data that may not be amenable 
to inclusion in a single-manuscript for-
mat. Frequently the researcher will make 
the raw data publicly available, either on an 
institution web site or in a public repository 
such as Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/). This allows 
other researchers with a speciﬁc interest in 
a particular pathway (for example, cytokine 
signaling) to examine the data to determine 
whether their gene or pathway of interest 
is involved (in this case, in leukocytes from 
patients with ANCA or SLE). It can also 
allow multiple small studies to be combined 
into much larger studies, providing greater 
statistical power to develop signature gene 
lists or study speciﬁc disease processes. We 
feel this represents an important enhance-
ment of peer-reviewed publications and 
should be done whenever possible.
In conclusion, when we pose the ques-
tion ‘Can I learn anything from this article?’ 
with regard to the article by Alcorta et al.,1 
we believe we can answer yes. The authors 
pull the data together quite well in the dis-
cussion section, where they link leukocyte 
gene expression with what is known about 
the immunologic mechanisms of ANCA 
(with neutrophils playing a major role in 
pathogenesis) and SLE (with T cells playing 
the major role). When microarray studies 
are designed well and the data analyzed 
appropriately, new and important insight 
can be obtained. Both writing and read-
ing these articles can be more challenging 
than conventional studies, but it is usually 
worth the eﬀort.
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Figure 1 | Gene expression changes in renal allograft biopsies from time 0 to 1 year after transplantation, demonstrating alterations in 
several genes involved in integrin and interferon signaling pathways, using a canonical pathway analysis. (a) Interferon signaling pathway.  
(b) Integrin signaling pathway. Significantly upregulated genes appear in red, downregulated in green, and unaltered genes are uncolored. 
(Reprinted with permission from ref. 4.)
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